Get the Stockscreener App
3.26
1.81%
-0.06
After Hours:
3.27
0.01
+0.31%
Sana Biotechnology Inc stock is traded at $3.26, with a volume of 2.82M.
It is down -1.81% in the last 24 hours and up +86.29% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
See More
Previous Close:
$3.32
Open:
$3.41
24h Volume:
2.82M
Relative Volume:
0.45
Market Cap:
$727.86M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-2.2177
EPS:
-1.47
Net Cash Flow:
$-273.61M
1W Performance:
-6.59%
1M Performance:
+86.29%
6M Performance:
-34.27%
1Y Performance:
-48.17%
1-Day Range:
$3.24
$3.44
1-Week Range:
$2.91
$3.65
52-Week Range:
$1.52
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.26 | 727.86M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Sana Biotechnology (NASDAQ:SANA) Trading Down 6.2%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Trading Up 8.8%What's Next? - MarketBeat
Vanguard Group Inc. Reduces Stake in Sana Biotechnology Inc. - GuruFocus.com
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why - Asianet Newsable
Sana Biotechnology, Inc. (SANA): A Bull Case Theory - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Up 13.9%Time to Buy? - MarketBeat
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Quantisnow
Sana Biotech extends rally as Morgan Stanley cites platform's potential - MSN
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Sana Biotechnology (NASDAQ:SANA) Trading Down 6.5%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Trading 13.9% HigherHere's Why - MarketBeat
Is Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock So Far In 2025? - MSN
There May Still Be Time to Get in on These 3 Trending Biotechs - MarketBeat
Sana Biotechnology Inc (SANA-Q) QuotePress Release - The Globe and Mail
JPMorgan Chase & Co. Cuts Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana stock rallies 280% on pancreatic cell transplant study - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Gap DownShould You Sell? - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Trading Down 5.5%Here's Why - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
As researchers push for a type 1 diabetes cure, Sana Biotechnology provides a nudge forward - STAT
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.5%Here's What Happened - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7%Here's Why - MarketBeat
Sana Biotechnology price target raised to $12 from $9 at Morgan Stanley - MSN
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7%Time to Buy? - MarketBeat
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025. - MSN
Sana Biotechnology Shows Promise with Hypoimmune Platform - TipRanks
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Barclays PLC - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Gap Up – Here’s What Happened - Defense World
Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $11.00 - Defense World
FMR LLC sells $1.89 million in Sana Biotechnology shares By Investing.com - Investing.com South Africa
SANA Stock Surges 152% In A Week On Upbeat Initial Diabetes Study Data - Barchart
FMR LLC Reduces Holdings in Sana Biotechnology Inc - GuruFocus.com
Insider Selling: Sana Biotechnology, Inc. (NASDAQ:SANA) Insider Sells 290,912 Shares of Stock - MarketBeat
FMR LLC sells $1.89 million in Sana Biotechnology shares - Investing.com India
Sana Biotechnology (NASDAQ:SANA) Shares Gap UpHere's What Happened - MarketBeat
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Sana Biotechnology could offer relief to diabetes type 1 sufferers in the future - Mugglehead
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):